Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia

Hemodialysis International

Volumn 14, Issue 1, 2010, Pages 47-54

  Bailie, George R ^a,b   Mason, Nancy A ^b,c   Valaoras, Thomas G ^d  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Renal Pharmacy Consultants LLC   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d Valaoras and Lewis Obstetrics and Gynecology   (United States)

Author keywords

Ferric carboxymaltose; Intravenous iron; Iron deficiency anemia; Safety

Indexed keywords

FERRIC CARBOXYMALTOSE; IRON COMPLEX; PLACEBO; UNCLASSIFIED DRUG; FERRIC ION; MALTOSE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL PNEUMONIA; BLOOD EXAMINATION; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MIGRAINE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; PHOSPHATE BLOOD LEVEL; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN TOXICITY; SMALL INTESTINE OBSTRUCTION; VITAL SIGN; ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; CHRONIC KIDNEY FAILURE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; ANEMIA, IRON-DEFICIENCY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FERRIC COMPOUNDS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MALTOSE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77349120060     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00409.x     Document Type: Article

References (10)

1. Brugnara C. Iron deficiency and erythropoiesis: New diagnostic approaches. Clin Chem 2003, 49:1573-1578.
2. Auerbach M, Coyne C, Ballard H. Intravenous iron: From anathema to standard of care. Am J Hematol 2008, 83:580-588.
3. Silverberg DS, Iaina A, Wexler D. The pathological consequences of anaemia. Clin Lab Haem 2001, 23:1-6.
4. Van Wyck DB, Eckhardt K-U, Adamson JW. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006, 47:S11-S15.
5. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet 2007, 370:511-520.
6. Fishbane S. Safety in iron management. Am J Kidney Dis 2003, 41((Suppl)):18-26.
7. Horl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007, 18:382-393.
8. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf, Common terminology criteria for adverse events v3.0. Available at, (accessed August 9, 2006)
9. Singh A, Patel T, Hertel J. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008, 52:907-915.
10. http://www.fda.gov/ohrms/dockets/AC/08/minutes/2008-4337m1-Final.pdf, Food and drug administration center for drug evaluation and research. Summary minutes of the drug safety and risk management advisory committee, February 1, 2008. Available at, (accessed October 27, 2008)